Triheptanoin
Triheptanoin is a pharmaceutical drug with 27 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
14
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
82.4%
14 of 17 finished
17.6%
3 ended early
2
trials recruiting
27
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Expanded Access to Triheptanoin
A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
Clinical Trials (27)
Expanded Access to Triheptanoin
A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood
Triheptanoin in Mc Ardle
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses
Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis
Treatment Development of Triheptanoin (G1D)
Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I
Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism
An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)
Post Study Continuation of C7 for G1D
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 27